AstraZeneca Announced At ESMO Sunday, TAGRISSO Plus Savolitinib Extended Median Overall Survival By Nearly Five Months In Patients With EGFRm Lung Cancer

Loading news article.

AstraZeneca Announced At ESMO Sunday, TAGRISSO Plus Savolitinib Extended Median Overall Survival By Nearly Five Months In Patients With EGFRm Lung Cancer | WAPE

AstraZeneca Announced At ESMO Sunday, TAGRISSO Plus Savolitinib Extended Median Overall Survival By Nearly Five Months In Patients With EGFRm Lung Cancer

Article summary

Related companies

Comments —